Non-HLA gene effects on the disease process of type 1 diabetes: From HLA susceptibility to overt disease

Journal of Autoimmunity

Volumn 61, Issue , 2015, Pages 45-53

  Lempainen, Johanna ^a   Laine, Antti Pekka ^a   Hammais, Anna ^a   Toppari, Jorma ^a   Simell, Olli ^a   Veijola, Riitta ^b   Knip, Mikael ^c,d,e   Ilonen, Jorma ^a,f  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d FOLKHÄLSAN RESEARCH CENTER   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Beta cell autoimmunity; Genetics; Progression; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; DEAD BOX PROTEIN; HLA DQ ANTIGEN; IFIH1 PROTEIN, HUMAN; PTPN2 PROTEIN, HUMAN; PTPN22 PROTEIN, HUMAN;

ADOLESCENT; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNITY; CELL DESTRUCTION; CHILD; CONTROLLED STUDY; DIABETOGENESIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HEREDITY; HUMAN; HUMORAL IMMUNITY; IKZF4 ERBB3 GENE; IMMUNOPATHOGENESIS; INFANT; INS GENE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NEWBORN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PTPN2 GENE; PTPN22 GENE; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; COHORT ANALYSIS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM; RISK FACTOR;

ALLELES; AUTOANTIBODIES; AUTOANTIGENS; COHORT STUDIES; DEAD-BOX RNA HELICASES; DIABETES MELLITUS, TYPE 1; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DQ ANTIGENS; HUMANS; INFANT, NEWBORN; INSULIN; INSULIN-SECRETING CELLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 2; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; RISK FACTORS;

EID: 84937517806     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.05.005     Document Type: Article

References (47)

1. Todd J.A., Walker N.M., Cooper J.D., Smyth D.J., Downes K., Plagnol V., et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 2007, 39:857-864.
2. Pociot F., Akolkar B., Concannon P., Erlich H.A., Julier C., Morahan G., et al. Genetics of type 1 diabetes: what's next?. Diabetes 2010, 59:1561-1571.
3. Knip M. Natural course of preclinical type 1 diabetes. Horm. Res. 2002, 57(Suppl. 1):6-11.
4. Knip M., Korhonen S., Kulmala P., Veijola R., Reunanen A., Raitakari O., et al. Prediction of type 1 diabetes in the general population. Diabetes Care 2010, 33:1206-1212.
5. Groop L., Pociot F. Genetics of diabetes - are we missing the genes or the disease?. Mol. Cell. Endocrinol. 2014, 382:726-739.
6. Kupila A., Muona P., Simell T., Arvilommi P., Savolainen H., Hämäläinen A.M., et al. Feasibility of genetic and immunological prediction of type i diabetes in a population-based birth cohort. Diabetologia 2001, 44:290-297.
7. Mikk M.L., Kiviniemi M., Laine A.P., Härkonen T., Veijola R., Simell O., et al. The hla-b39 allele increases type 1 diabetes risk conferred by hla-drb104:04-dqb103:02 and hla-drb108-dqb104 class ii haplotypes. Hum. Immunol. 2014, 75:65-70.
8. Kukko M., Kimpimäki T., Korhonen S., Kupila A., Simell S., Veijola R., et al. Dynamics of diabetes-associated autoantibodies in young children with human leukocyte antigen-conferred risk of type 1 diabetes recruited from the general population. J. Clin. Endocrinol. Metab. 2005, 90:2712-2717.
9. Surveillance WHODoND Part 1: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications 1999, World Health Org., Geneva, Switzerland.
10. Hermann R., Turpeinen H., Laine A.P., Veijola R., Knip M., Simell O., et al. Hla dr-dq-encoded genetic determinants of childhood-onset type 1 diabetes in Finland: an analysis of 622 nuclear families. Tissue Antigens 2003, 62:162-169.
11. Kiviniemi M., Hermann R., Nurmi J., Ziegler A.G., Knip M., Simell O., et al. A high-throughput population screening system for the estimation of genetic risk for type 1 diabetes: an application for the teddy (the environmental determinants of diabetes in the young) study. Diabetes Technol. Ther. 2007, 9:460-472.
12. Hekkala A., Ilonen J., Knip M., Veijola R. Family history of diabetes and distribution of class ii hla genotypes in children with newly diagnosed type 1 diabetes: effect on diabetic ketoacidosis. Eur. J. Endocrinol. 2011, 165:813-817.
13. Siljander H.T., Simell S., Hekkala A., Lähde J., Simell T., Vahasalo P., et al. Predictive characteristics of diabetes-associated autoantibodies among children with hla-conferred disease susceptibility in the general population. Diabetes 2009, 58:2835-2842.
14. Benjamini E.H.Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc., Ser. B Stat. Methodol. 1995, 57:289-300.
15. Ilonen J., Hammais A., Laine A.P., Lempainen J., Vaarala O., Veijola R., et al. Patterns of beta-cell autoantibody appearance and genetic associations during the first years of life. Diabetes 2013, 62:3636-3640.
16. Lempainen J., Härkonen T., Laine A., Knip M., Ilonen J. Associations of polymorphisms in non-hla loci with autoantibodies at the diagnosis of type 1 diabetes: Ins and ikzf4 associate with insulin autoantibodies. Pediatr. Diabetes 2013, 14:490-496.
17. Torn C., Hadley D., Lee H.S., Hagopian W., Lernmark A., Simell O., et al. Role of type 1 diabetes associated snps on risk of autoantibody positivity in the teddy study. Diabetes 2015, 64:1818-1829.
18. Steck A.K., Wong R., Wagner B., Johnson K., Liu E., Romanos J., et al. Effects of non-hla gene polymorphisms on development of islet autoimmunity and type 1 diabetes in a population with high-risk hla-dr,dq genotypes. Diabetes 2012, 61:753-758.
19. Steck A.K., Zhang W., Bugawan T.L., Barriga K.J., Blair A., Erlich H.A., et al. Do non-hla genes influence development of persistent islet autoimmunity and type 1 diabetes in children with high-risk hla-dr,dq genotypes?. Diabetes 2009, 58:1028-1033.
20. Walter M., Albert E., Conrad M., Keller E., Hummel M., Ferber K., et al. Iddm2/insulin vntr modifies risk conferred by iddm1/hla for development of type 1 diabetes and associated autoimmunity. Diabetologia 2003, 46:712-720.
21. Hermann R., Laine A.P., Veijola R., Vahlberg T., Simell S., Lähde J., et al. The effect of hla class ii, insulin and ctla4 gene regions on the development of humoral beta cell autoimmunity. Diabetologia 2005, 48:1766-1775.
22. Hermann R., Lipponen K., Kiviniemi M., Kakko T., Veijola R., Simell O., et al. Lymphoid tyrosine phosphatase (lyp/ptpn22) arg620trp variant regulates insulin autoimmunity and progression to type 1 diabetes. Diabetologia 2006, 49:1198-1208.
23. Steck A.K., Dong F., Wong R., Fouts A., Liu E., Romanos J., et al. Improving prediction of type 1 diabetes by testing non-hla genetic variants in addition to hla markers. Pediatr. Diabetes 2014, 15:355-362.
24. Vafiadis P., Bennett S.T., Todd J.A., Nadeau J., Grabs R., Goodyer C.G., et al. Insulin expression in human thymus is modulated by ins vntr alleles at the iddm2 locus. Nat. Genet. 1997, 15:289-292.
25. Pugliese A. Central and peripheral autoantigen presentation in immune tolerance. Immunology 2004, 111:138-146.
26. Pugliese A., Zeller M., Fernandez A., Zalcberg L.J., Bartlett R.J., Ricordi C., et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the ins vntr-iddm2 susceptibility locus for type 1 diabetes. Nat. Genet. 1997, 15:293-297.
27. Lempainen J., Hermann R., Veijola R., Simell O., Knip M., Ilonen J. Effect of the ptpn22 and ins risk genotypes on the progression to clinical type 1 diabetes after the initiation of beta-cell autoimmunity. Diabetes 2012, 61:963-966.
28. Winkler C., Lauber C., Adler K., Grallert H., Illig T., Ziegler A., et al. An interferon-induced helicase (ifih1) gene polymorphism associates with different rates of progression from autoimmunity to type 1 diabetes. Diabetes 2011, 60:685-690.
29. Gregersen P.K., Lee H.S., Batliwalla F., Begovich A.B. Ptpn22: setting thresholds for autoimmunity. Semin. Immunol. 2006, 18:214-223.
30. Burn G.L., Svensson L., Sanchez-Blanco C., Saini M., Cope A.P. Why is ptpn22 a good candidate susceptibility gene for autoimmune disease?. FEBS Lett. 2011, 585:3689-3698.
31. Yoneyama M., Fujita T. RNA recognition and signal transduction by RIG-I-like receptors. Immunol. Rev. 2009, 227:54-65.
32. Salminen K., Sadeharju K., Lönnrot M., Vähäsalo P., Kupila A., Korhonen S., et al. Enterovirus infections are associated with the induction of beta-cell autoimmunity in a prospective birth cohort study. J. Med. Virol. 2003, 69:91-98.
33. Lönnrot M., Korpela K., Knip M., Ilonen J., Simell O., Korhonen S., et al. Enterovirus infection as a risk factor for beta-cell autoimmunity in a prospectively observed birth cohort: the Finnish Diabetes Prediction and Prevention Study. Diabetes 2000, 49:1314-1318.
34. Lönnrot M., Salminen K., Knip M., Savola K., Kulmala P., Leinikki P., et al. Enterovirus rna in serum is a risk factor for beta-cell autoimmunity and clinical type 1 diabetes: a prospective study. Childhood diabetes in Finland (dime) study group. J. Med. Virol. 2000, 61:214-220.
35. Fuchtenbusch M., Irnstetter A., Jager G., Ziegler A.G. No evidence for an association of coxsackie virus infections during pregnancy and early childhood with development of islet autoantibodies in offspring of mothers or fathers with type 1 diabetes. J. Autoimmun. 2001, 17:333-340.
36. Graves P.M., Rotbart H.A., Nix W.A., Pallansch M.A., Erlich H.A., Norris J.M., et al. Prospective study of enteroviral infections and development of beta-cell autoimmunity. Diabetes autoimmunity study in the young (daisy). Diabetes Res. Clin. Pract. 2003, 59:51-61.
37. Bonifacio E., Warncke K., Winkler C., Wallner M., Ziegler A.G. Cesarean section and interferon-induced helicase gene polymorphisms combine to increase childhood type 1 diabetes risk. Diabetes 2011, 60:3300-3306.
38. Ziegler A.G., Rewers M., Simell O., Simell T., Lempainen J., Steck, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013, 309:2473-2479.
39. Smyth D.J., Plagnol V., Walker N.M., Cooper J.D., Downes K., Yang J.H., et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N. Engl. J. Med. 2008, 359:2767-2777.
40. Laine A.P., Knip M., Ilonen J. Transmission disequilibrium analysis of 31 type 1 diabetes susceptibility loci in Finnish families. Tissue Antigens 2013, 82:35-42.
41. Santin I., Moore F., Colli M.L., Gurzov E.N., Marselli L., Marchetti P., et al. Ptpn2, a candidate gene for type 1 diabetes, modulates pancreatic beta-cell apoptosis via regulation of the bh3-only protein bim. Diabetes 2011, 60:3279-3288.
42. Wiede F., Ziegler A., Zehn D., Tiganis T. Ptpn2 restrains cd8(+) t cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice. J. Autoimmun. 2014, 53:105-114.
43. Song G., Bae S.C., Choi S., Ji J., Lee Y. Association between the cd226 rs763361 polymorphism and susceptibility to autoimmune diseases: a meta-analysis. Lupus 2012, 21:1522-1530.
44. Lofgren S.E., Delgado-Vega A.M., Gallant C.J., Sanchez E., Frostegard J., Truedsson L., et al. A 3'-untranslated region variant is associated with impaired expression of cd226 in t and natural killer t cells and is associated with susceptibility to systemic lupus erythematosus. Arthritis Rheum. 2010, 62:3404-3414.
45. Winkler C., Krumsiek J., Lempainen J., Achenbach P., Grallert H., Giannopoulou E., et al. A strategy for combining minor genetic susceptibility genes to improve prediction of disease in type 1 diabetes. Genes Immun. 2012, 13:549-555.
46. Douroudis K., Laine A.P., Heinonen M., Hermann R., Lipponen K., Veijola R., et al. Association of ctla4 but not icos polymorphisms with type 1 diabetes in two populations with different disease rates. Hum. Immunol. 2009, 70:536-539.
47. Pan F., Yu H., Dang E.V., Barbi J., Pan X., Grosso J.F., et al. Eos mediates foxp3-dependent gene silencing in cd4+ regulatory t cells. Science 2009, 325:1142-1146.